Gastrointestinal stromal tumor (GIST) · line 2 · Sunitinib monotherapy (GIST 2L; imatinib-resistant/intolerant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-SUNITINIB-GIST-2L |
| ID | IND-GIST-2L-SUNITINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-GIST |
| Sources | SRC-NCCN-GIST-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard 2L GIST after imatinib failure (non-PDGFRA D842V). Sunitinib registered in Ukraine (Sutent). NSZU may reimburse for GIST indication — verify current coverage.
Used By
Algorithms
ALGO-GIST-2L- ALGO-GIST-2L